30,208 Shares in Zoetis Inc. $ZTS Purchased by Qsemble Capital Management LP

Qsemble Capital Management LP purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 30,208 shares of the company’s stock, valued at approximately $2,171,000.

Several other large investors have also recently bought and sold shares of ZTS. Brighton Jones LLC lifted its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the last quarter. Empowered Funds LLC grew its position in shares of Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC grew its position in shares of Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC increased its stake in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co increased its stake in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 2.9%

NYSE ZTS opened at $73.64 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 1-year low of $71.45 and a 1-year high of $160.48. The company has a 50 day moving average of $76.30 and a 200-day moving average of $99.01. The company has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 1.31 and a beta of 0.74.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio is presently 34.93%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. Argus reissued a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. HSBC lowered their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. William Blair reissued a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, Stifel Nicolaus decreased their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.